Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Awareness programs
View:
Post by Pimpovish on Dec 31, 2020 10:35am

Awareness programs

Hopefully the company has US awareness lined up for 2021. Also, an outreach for analyst coverage is highly recommended. The analysts will help in connecting all the dots and transparently demonstrate the opportunity for a massive ROI. I actually see eye to eye with the CEO in value assessment. I have now exhaustingly reviewed a dozen other companies that are trading far far higher than HEM and have concluded a  $7 share price is a reasonable target given the IP and sector dynamics. This is my opinion as a sophisticated investor. But i suspect many others are coming to a similar rationalization. When the institutional buying begins in earnest on this stock, the moves should prove to be dramatic. Thr tightened float and strong long investor belief will serve as formidable anchors.
Comment by Walterthedog on Dec 31, 2020 10:48am
The CEO has stated several times the importance of the midpoint data and I tend to agree. The interim data provided shows how effective ACP is but the midpoint data will be concrete scientific proof that should drive our value higher and prove the efficacy of the product to anyone still in doubt. Anyone interested in making real money should probably get in ASAP as these results should be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities